

IN THE CLAIMS:

All claims currently pending and under consideration in the referenced application are shown in the listing of claims and will replace all prior versions and listings of claims in the application. Claims 1, 21, 36, 38, 39, 45 and 52 were previously withdrawn from consideration. Claims 2-20, 22-35 and 37 were previously cancelled. Claims 36, 38 and 40 have been amended herein. Claims 1, 21, 41 and 46-49 have been cancelled herein. All amendments have been made without prejudice or disclaimer. No new matter has been added. Please enter these claims as amended.

Listing of the Claims:

1-35. (Cancelled)

36. (Withdrawn) (Currently amended) A kit for determining activity of a protease in a sample, said kit comprising:

at least one viral protein or virus produced by a process for producing said ~~virus~~
~~and/or~~ at least one viral protein or virus, said process comprising:

providing a cell with at least a sequence encoding at least one gene product of an adenoviral E1 gene or a functional derivative of said adenoviral E1 ~~gene~~,
gene;

providing said cell with a nucleic acid sequence encoding said ~~desired virus and/or said desired~~ at least one viral proteins, protein or virus;

culturing said cell in a suitable medium and allowing for expression of said ~~virus and/or said viral proteins~~, at least one viral protein or virus; and

harvesting said ~~virus and/or~~ at least one viral proteins ~~protein or virus~~
from said suitable medium and/or said cell.

37. (Cancelled)

38. (Withdrawn) (Currently amended) The kit ~~of~~ according to claim 36, wherein said protease comprises trypsin.

39. (Withdrawn) The kit according to claim 36, wherein said sample comprises culture medium.

40. (Currently amended) A method for concentrating an influenza virus that is or can be made infectious ~~under conditions capable of at least in part preserving virus infectivity~~, said method comprising:

obtaining a ~~cell-cleared~~ cell-cleared supernatant comprising said influenza virus from a culture of ~~cells~~, cells; ~~and~~

ultrafiltrating said supernatant under low shear conditions using a hollow fiber; and

concentrating the virus.

41. (Cancelled)

42. (Previously presented) The method according to claim 40, wherein said culture of cells comprises *in vitro* cultured cells.

43. (Previously presented) The method according to claim 40, wherein said ultrafiltrating is performed with a filter comprising a cut-off of 750 KD.

44. (Previously presented) The method according to claim 40, wherein said concentrating further comprises at least a partial removal of proteins comprising a molecular weight smaller than 750 KD.

45. (Withdrawn) Infectious influenza virus or derivatives thereof produced by a method according to claim 40.

46-49. (Cancelled)

50. (Previously presented) The method according to claim 42, wherein said concentrating further comprises at least a partial removal of proteins comprising a molecular weight smaller than 750 KD.

51. (Previously presented) The method according to claim 43, wherein said concentrating further comprises at least a partial removal of proteins comprising a molecular weight smaller than 750 KD.

52. (Withdrawn) Infectious influenza virus concentrated by the method according to claim 41.